Stawicki, Sabina

[["dc.bibliographiccitation.firstpage","92"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Alcohol and Alcoholism"],["dc.bibliographiccitation.lastpage","102"],["dc.bibliographiccitation.volume","42"],["dc.contributor.author","Bartels, Claudia"],["dc.contributor.author","Kunert, Hanns-Jürgen"],["dc.contributor.author","Stawicki, Sabina"],["dc.contributor.author","Kröner-Herwig, Birgit"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.contributor.author","Krampe, Henning"],["dc.date.accessioned","2017-09-07T11:46:30Z"],["dc.date.available","2017-09-07T11:46:30Z"],["dc.date.issued","2007"],["dc.description.abstract","The hippocampus (HC) is characterized by high vulnerability to noxious influence, but also by a considerable regenerative potential. Although deficits in HC-related functions are among the most commonly reported cognitive sequelae in alcoholism, little and conflicting information is available concerning regeneration upon abstinence. The present study has been designed to evaluate (i) the frequency of measurable dysfunction in so called HC tests and (ii) its predictive value for risk to relapse in a cohort of 50 severely affected chronic alcoholic patients and (iii) to monitor recovery of HC-related functions upon strict abstention from alcohol. Patients underwent a 2-year neuropsychological follow-up including HC-associated tests (Verbal Learning Test, VLT; Nonverbal Learning Test, NVLT; 'City Map Test' of Learning and Memory Test, LGT-3), as well as tests of intelligence and attention in the framework of OLITA (Outpatient Long-Term Intensive Therapy for Alcoholics), a programme with careful abstinence monitoring. At study entry, 30/50 (60%) alcoholics had HC dysfunction which tended to predict a lower long-term abstinence probability (P = 0.058). Of the subgroup that could be followed under conditions of strictly monitored alcohol abstinence (n = 32; age 44.7 +/- 6.2 years; 23 men, 9 women), 53% (17/32) exhibited distinct HC dysfunction at inclusion which returned to normal after 2 years. Patients with initially normal HC function (9/32) and patients with additional brain damage of different aetiologies (6/32) failed to show improvement on HC-related tests. While the former displayed stably normal HC test performance, the latter remained on a performance level below normal. Demonstrating slow but remarkable regeneration of HC functions upon strict abstention from alcohol, our data strongly support abstinence-oriented long-term treatment of alcoholics. The absence of functional recovery in patients with additional causes of brain damage might be explained by the 'dual hit' exhausting the regenerative potential of the HC."],["dc.identifier.doi","10.1093/alcalc/agl104"],["dc.identifier.gro","3150510"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/7282"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.relation.issn","0735-0414"],["dc.title","Recovery of hippocampus-related functions in chronic alcoholics during monitored long-term abstinence"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","86"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Alcoholism: Clinical and Experimental Research"],["dc.bibliographiccitation.lastpage","95"],["dc.contributor.author","Krampe, Henning"],["dc.contributor.author","Stawicki, Sabina"],["dc.contributor.author","Wagner, Thilo"],["dc.contributor.author","Bartels, Claudia"],["dc.contributor.author","Aust, Carlotta"],["dc.contributor.author","Rüther, Eckart"],["dc.contributor.author","Poser, Wolfgang"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.date.accessioned","2017-09-07T11:46:33Z"],["dc.date.available","2017-09-07T11:46:33Z"],["dc.date.issued","2006"],["dc.description.abstract","Objective: (1) To perform a 9-year study of abstinence, lapse, and relapse in 180 chronic alcoholic patients, participants of the Outpatient Longterm Intensive Therapy for Alcoholics (OLITA); (2) To investigate the role of supervised alcohol deterrents (AD) in relapse prevention and as an adjunct for maintenance of long-term abstinence. Method: This prospective open treatment study evaluates the long-term course of drinking outcomes and AD use of 180 chronic alcoholics consecutively admitted from 1993 to 2002. Subsamples are compared for (1) sham-AD versus verum-AD (disulfiram/calcium carbimide), (2) coped lapses versus finally detrimental lapses versus malignant relapses, and (3) AD use for 13 to 20 versus {.extbackslash}textgreater 20 months. Results: In this 9-year study, the cumulative probability of not having relapsed was 0.52, and that of not having consumed any alcohol was 0.26. Despite long-term use, disulfiram/calcium carbimide was well tolerated. Patients on sham-AD (due to contraindications to verum-AD) showed higher cumulative abstinence probability than patients on verum (S {.extbackslash}textequals 0.86 vs. S {.extbackslash}textequals 0.49, p {.extbackslash}textequals 0.03). Detrimental lapses and malignant relapses occurred earlier than successfully coped lapses (p {.extbackslash}textless 0.001); patients with detrimental lapse and with malignant relapse had rewer days of AD intake and less subsequent days without AD than patients with coped lapse (p {.extbackslash}textless 0.001). The cumulative abstinence probability was S {.extbackslash}textequals 0.75 for patients with long-term intake compared with S {.extbackslash}textequals 0.50 for patients who stopped AD between months 13 and 20 (p {.extbackslash}textless 0.001). Conclusions: An abstinence rate of {.extbackslash}textgreater 50{.extbackslash}textpercent in this 9-year study strongly supports the concept of comprehensive, long-term outpatient treatment of alcoholics. Supervised, guided intake of AD, also over extended periods, can be used as a predominantly psychologically acting ingredient of successful alcoholism therapy."],["dc.identifier.doi","10.1111/j.1530-0277.2006.00013.x"],["dc.identifier.gro","3150523"],["dc.identifier.pmid","16433735"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/7295"],["dc.language.iso","en"],["dc.notes.status","zu prüfen"],["dc.relation.issn","0145-6008"],["dc.title","Follow-up of 180 alcoholic patients for up to 7 years after outpatient treatment: Impact of alcohol deterrents on outcome"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","146"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal of Renal Nutrition"],["dc.bibliographiccitation.lastpage","153"],["dc.bibliographiccitation.volume","18"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.contributor.author","Bartels, Claudia"],["dc.contributor.author","Sargin, Derya"],["dc.contributor.author","Stawicki, Sabina"],["dc.contributor.author","Krampe, Henning"],["dc.date.accessioned","2017-09-07T11:46:29Z"],["dc.date.available","2017-09-07T11:46:29Z"],["dc.date.issued","2008"],["dc.description.abstract","Treatment of human brain disease with erythropoietin (EPO) in order to achieve neuroprotection and/or neuroregeneration represents a totally new frontier in translational neuroscience. Rather than specifically targeting the cause of a particular disease entity, EPO nonspecifically influences components of the “final common pathway” that determine disease severity and progression in a number of entirely different brain diseases. EPO acts in an antiapoptotic, anti-inflammatory, antioxidant, neurotrophic, angiogenetic, stem cell–modulatory fashion. Importantly, it appears to influence neural plasticity. Most likely due to these properties, EPO has been found by many investigators to be protective or regenerative and to improve cognitive performance in various rodent models of neurological and psychiatric disease. The “Göttingen-EPO-stroke trial” has provided first promising data on humans for a neuroprotective therapy of an acute brain disease. Experimental EPO treatment to improve cognitive function in patients with schizophrenia represents a novel neuroregenerative strategy for a chronic brain disease. An exploratory trial in chronic progressive multiple sclerosis as an example of an inflammatory disease of the nervous system yielded first positive results of EPO treatment on both motor function and cognition. These promising results are just the beginning and will hopefully stimulate further work along these lines."],["dc.identifier.doi","10.1053/j.jrn.2007.10.029"],["dc.identifier.gro","3150511"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/7283"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.title","Recombinant human erythropoietin in the treatment of human brain disease: focus on cognition"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","708"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Psychiatric Services"],["dc.bibliographiccitation.lastpage","712"],["dc.bibliographiccitation.volume","57"],["dc.contributor.author","Krampe, Henning"],["dc.contributor.author","Wagner, Thilo"],["dc.contributor.author","Stawicki, Sabina"],["dc.contributor.author","Bartels, Claudia"],["dc.contributor.author","Aust, Carlotta"],["dc.contributor.author","Kroener-Herwig, Birgit"],["dc.contributor.author","Kuefner, Heinrich"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.date.accessioned","2021-06-01T10:47:52Z"],["dc.date.available","2021-06-01T10:47:52Z"],["dc.date.issued","2006"],["dc.description.abstract","Objective: A prospective four-year study examined which components of addiction severity predicted time to relapse among 112 adults with chronic alcoholism who participated in a comprehensive outpatient treatment program. Methods: Recruited from emergency, inpatient, and outpatient facilities, patients were admitted into the program consecutively between March 1998 and June 2002. Alcohol abstinence was carefully monitored for four years from admission by regular contacts and urine and blood analyses. Alcoholism characteristics and personality disorders were assessed with structured interviews and the International Diagnostic Checklists for Personality Disorders. Results: Among a variety of potential variables, only presence of a personality disorder and chronicity of addiction were independently associated with a decrease of cumulative four-year abstinence probability. Conclusions: Their high predictive values suggest that chronicity and personality disorder rank among the most important characteristics of addiction severity."],["dc.identifier.doi","10.1176/ps.2006.57.5.708"],["dc.identifier.gro","3150525"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85746"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.notes.status","final"],["dc.relation.eissn","1557-9700"],["dc.relation.issn","1075-2730"],["dc.subject","addiction severity; relapse; alcoholism treatment; personality disorder; prediction; addiction chronicity; 2006; Alcohol Rehabilitation; Alcoholism; Personality Disorders; Relapse (Disorders); Severity (Disorders); Chronicity (Disorders)"],["dc.title","Personality Disorder and Chronicity of Addiction as Independent OutcomePredictors in Alcoholism Treatment"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Pharmacopsychiatry"],["dc.bibliographiccitation.volume","40"],["dc.contributor.author","Krampe, Henning"],["dc.contributor.author","Stawicki, Sabina"],["dc.contributor.author","Niehaus, S."],["dc.contributor.author","Ribbe, K."],["dc.contributor.author","Wagner, T."],["dc.contributor.author","Bartels, C."],["dc.contributor.author","Kroener-Herwig, Birgit"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.date.accessioned","2018-11-07T10:59:23Z"],["dc.date.available","2018-11-07T10:59:23Z"],["dc.date.issued","2007"],["dc.format.extent","235"],["dc.identifier.isi","000249873600151"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/50685"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.publisher.place","Stuttgart"],["dc.relation.conference","25th Symposium of the Arbeitsgemeinschaft-Neuropsychopharmakologie-und-Pharmakopsychiatrie"],["dc.relation.eventlocation","Munich, GERMANY"],["dc.relation.issn","0176-3679"],["dc.title","Prediction of outcome by multimodal monitoring of treatment processes in alcoholism therapy"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","546"],["dc.bibliographiccitation.issue","9-10"],["dc.bibliographiccitation.journal","Molecular Medicine"],["dc.bibliographiccitation.lastpage","552"],["dc.bibliographiccitation.volume","14"],["dc.contributor.author","Begemann, Martin"],["dc.contributor.author","Sargin, Derya"],["dc.contributor.author","Rossner, Moritz J."],["dc.contributor.author","Bartels, Claudia"],["dc.contributor.author","Theis, Fabian"],["dc.contributor.author","Wichert, Sven P."],["dc.contributor.author","Stender, Nike"],["dc.contributor.author","Fischer, Benjamin"],["dc.contributor.author","Sperling, Swetlana"],["dc.contributor.author","Stawicki, Sabina"],["dc.contributor.author","Wiedl, Anne"],["dc.contributor.author","Falkai, Peter"],["dc.contributor.author","Nave, Klaus-Armin"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.date.accessioned","2017-09-07T11:46:37Z"],["dc.date.available","2017-09-07T11:46:37Z"],["dc.date.issued","2008"],["dc.description.abstract","Molecular mechanisms underlying bipolar affective disorders are unknown. Difficulties arise from genetic and phenotypic heterogeneity of patients and the lack of animal models. Thus, we focused on only one patient (n = 1) with an extreme form of rapid cycling, Ribonucleic acid (RNA) from peripheral blood mononuclear cells (PBMC) was analyzed in a three-tiered approach under widely standardized conditions. Firstly, RNA was extracted from PBMC of eight blood samples, obtained on two consecutive days within one particular episode, including two different consecutive depressive and two different consecutive manic episodes, and submitted to (1) screening by microarray hybridizations, followed by (2) detailed bioinformatic analysis, and (3) confirmation of episode-specific regulation of genes by quantitative real-time polymerase chain reaction (qRT-PCR). Secondly, results were validated in additional blood samples obtained one to two years later. Among gene transcripts elevated in depressed episodes were prostaglandin D synthetase (PTGDS) and prostaglandin D2 11-ketoreductase (AKR1C3), both involved in hibernation. We hypothesized them to account for some of the rapid cycling symptoms. A subsequent treatment approach over 5 months applying the cyclooxygenase inhibitor celecoxib (2 x 200 mg daily) resulted in reduced severity rating of both depressed and manic episodes. This case suggests that rapid cycling is a systemic disease, resembling hibernation, with prostaglandins playing a mediator role."],["dc.identifier.doi","10.2119/2008-00053.Begemann"],["dc.identifier.gro","3150556"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/7331"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.subject","Bipolar Disorder; Inhibitor Celecoxib; Prostaglandin D-2; Major Depression; Double-Blind; Hibernation; Sleep; Indomethacin; Hippocampus; Neurons"],["dc.title","Episode-specific differential gene expression of peripheral blood mononuclear cells in rapid cycling supports novel treatment approaches"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Pharmacopsychiatry"],["dc.bibliographiccitation.volume","38"],["dc.contributor.author","Krampe, Henning"],["dc.contributor.author","Stawicki, Sabina"],["dc.contributor.author","Wagner, T."],["dc.contributor.author","Bartels, C."],["dc.contributor.author","Ruther, Eckart"],["dc.contributor.author","Poser, Wolfgang"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.date.accessioned","2018-11-07T10:56:35Z"],["dc.date.available","2018-11-07T10:56:35Z"],["dc.date.issued","2005"],["dc.format.extent","257"],["dc.identifier.isi","000232591900140"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/50048"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.publisher.place","Stuttgart"],["dc.relation.conference","24th Symposium of the Arbeitsgemeinschaft-fur-Neuropsychopharmakologie-und-Pharmakopsychiatrie (AGNP)"],["dc.relation.eventlocation","Munich, GERMANY"],["dc.relation.issn","0176-3679"],["dc.title","Longterm follow-up of 180 chronic alcoholics during and after comprehensive integrated outpatient treatment: Relation of deterrent medication (DM) and outcome"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","27"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Suchtmedizin in Forschung und Praxis"],["dc.bibliographiccitation.lastpage","47"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Stawicki, Sabina"],["dc.contributor.author","Krampe, Henning"],["dc.contributor.author","Niehaus, Silja"],["dc.contributor.author","Ribbe, Katja"],["dc.contributor.author","Wagner, Thilo"],["dc.contributor.author","Bartels, Claudia"],["dc.contributor.author","Kröner-Herwig, Birgit"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.date.accessioned","2017-09-07T11:46:31Z"],["dc.date.available","2017-09-07T11:46:31Z"],["dc.date.issued","2007"],["dc.description.abstract","Background: Research on addiction treatment lacks prospectivelongitudinal studies that analyze with observational instrumentsbehavior of alcohol dependent patients during therapy sessions.With the \"Video-Assisted Monitoring of Psychotherapeutic pro-cesses in chronic psychiatric disease (VAMP)\" this study investi-gates 64 chronic alcohol dependent patients at three time-points,t1 (week 3), t2 (month 6), and t3 (month 12) during the first year ofthe Outpatient Longterm Intensive Therapy for Alcoholics (OLITA).Aims: Change of therapeutic processes between t1, t2, and t3,prediction of cumulative abstinence probability during a follow-up of up to 4 years, construction of the TOPPS ( Therapy Orientationby Process Prediction Score).Methods: 175 video recordings of therapy sessions were analyzedwith the VAMP. After each video recording, patients and therapistsrated their experience of the therapeutic alliance. Change oftherapeutic processes over time were tested with repeatedmeasures ANOVA, and prediction of cumulative abstinence pro-bability by therapy processes was determined with Cox Regressi-on Analysis.Results: Most of the processes changed only marginally betweent1, t2 and t3. The TOPPS predicts cumulative abstinence probabilityat all of the three time-points (p < 0,001) by integrating eightprocess variables with the highest predictive validity: Experienceof ressources, abstinence self-efficacy, implicit craving, relapsealertness, relapse risk, disease concept, dysfunctional therapeuticengagement, dysfunctional problem solving of current problems.Patients who relapsed after 12 months showed continuously lowTOPPS from t1 to t3. However, patients who maintained long-termabstinence had high TOPPS at t1 which increased slightly betweent2 and t3 (p < 0,015).Conclusions: The eight TOPPS processes are determined from thecurrent behavior of a patient during a specific therapy session andindicate to which extent his common behavior predicts probabi-lity of longterm abstinence or relapse risk. The results suggest toemploy the TOPPS in addiction therapy as a guideline of indivi-dual relapse prevention strategies."],["dc.identifier.gro","3150528"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/7301"],["dc.language.iso","de"],["dc.notes.status","final"],["dc.subject","Behavior observation; HAQ; Helping Alliance Question- naire; processes of change; psychotherapy of alcohol dependence; therapy process and outcome research"],["dc.subject","Psychotherapie der Alkoholabhängigkeit; HAQ; Helping Alliance Questionnaire; Therapieprozess-Forschung; Ver- änderungsprozesse; Verhaltensbeobachtung"],["dc.title","Multimodales Monitoring psychotherapeutischer Prozesse in der Behandlung alkoholkranker Patienten"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","30"],["dc.bibliographiccitation.journal","Journal of Psychiatric Research"],["dc.bibliographiccitation.lastpage","47"],["dc.contributor.author","Krampe, Henning"],["dc.contributor.author","Stawicki, Sabina"],["dc.contributor.author","Ribbe, Katja"],["dc.contributor.author","Wagner, Thilo"],["dc.contributor.author","Bartels, Claudia"],["dc.contributor.author","Kroener-Herwig, Birgit"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.date.accessioned","2017-09-07T11:46:32Z"],["dc.date.available","2017-09-07T11:46:32Z"],["dc.date.issued","2008"],["dc.description.abstract","Outcome prediction in alcoholism therapy is of major sociopolitical and economic significance. Instruments based on psychotherapeutic processes are lacking. Therefore, treatment processes of 64 chronic alcohol dependent patients have been investigated at three time-points, t1 (week 3), t2 (month 6), and t3 (month 12) during the first year of a comprehensive outpatient treatment program, guaranteeing strictly controlled alcohol abstinence. Main focus of the study was the prediction of cumulative abstinence probability over a follow-up period of up to 4 years based on these treatment processes. One hundred and seventy-five video recordings of therapy sessions were analyzed with the behavior observational system VAMP (Video-Assisted Monitoring of Psychotherapeutic Processes in Chronic Psychiatric Disease). Patients’ self-rating of treatment processes was measured with questionnaires for self-efficacy, abstinence confidence, self-consciousness and stress coping. Prediction of cumulative abstinence probability was determined with Cox regression analysis. By integrating the observer rated process variables with the highest predictive validity, the composite score TOPPS (Therapy Orientation by Process Prediction Score) was constructed. It includes the process variables experience of resources, abstinence self-efficacy, implicit craving, relapse alertness, relapse risk, disease concept, dysfunctional therapeutic engagement, and dysfunctional problem solving of current problems. Whereas patients’ self-rating of treatment processes was insufficiently predictive, the TOPPS strongly predicted four-year abstinence probability at any of the 3 time-points (p < 0.001). The results suggest to validate the item combination described in the TOPPS in addiction therapy as a treatment guideline of individual relapse prevention strategies."],["dc.identifier.doi","10.1016/j.jpsychires.2008.01.007"],["dc.identifier.gro","3150530"],["dc.identifier.pmid","18342335"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/7302"],["dc.language.iso","en"],["dc.notes.status","zu prüfen"],["dc.title","Development of an outcome prediction measure for alcoholism therapy by multimodal monitoring of treatment processes"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","26"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Molecular Psychiatry"],["dc.bibliographiccitation.lastpage","36"],["dc.bibliographiccitation.volume","16"],["dc.contributor.author","Wüstenberg, Torsten"],["dc.contributor.author","Begemann, Martin"],["dc.contributor.author","Bartels, Claudia"],["dc.contributor.author","Gefeller, Olaf"],["dc.contributor.author","Stawicki, S."],["dc.contributor.author","Hinze-Selch, D."],["dc.contributor.author","Mohr, Alexander"],["dc.contributor.author","Falkai, Peter"],["dc.contributor.author","Aldenhoff, Josef B."],["dc.contributor.author","Knauth, Michael"],["dc.contributor.author","Nave, Klaus-Armin"],["dc.contributor.author","Ehrenreich, Hanhelore"],["dc.date.accessioned","2017-09-07T11:46:27Z"],["dc.date.available","2017-09-07T11:46:27Z"],["dc.date.issued","2011"],["dc.description.abstract","Neurodevelopmental abnormalities together with neurodegenerative processes contribute to schizophrenia, an etiologically heterogeneous, complex disease phenotype that has been difficult to model in animals. The neurodegenerative component of schizophrenia is best documented by magnetic resonance imaging (MRI), demonstrating progressive cortical gray matter loss over time. No treatment exists to counteract this slowly proceeding atrophy. The hematopoietic growth factor erythropoietin (EPO) is neuroprotective in animals. Here, we show by voxel-based morphometry in 32 human subjects in a placebo-controlled study that weekly high-dose EPO for as little as 3 months halts the progressive atrophy in brain areas typically affected in schizophrenia, including hippocampus, amygdala, nucleus accumbens, and several neocortical areas. Specifically, gray matter protection is highly associated with improvement in attention and memory functions. These findings suggest that a neuroprotective strategy is effective against common pathophysiological features of schizophrenic patients, and strongly encourage follow-up studies to optimize EPO treatment dose and duration."],["dc.identifier.doi","10.1038/mp.2010.51"],["dc.identifier.gro","3150516"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6267"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/7289"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject","hematopoietic growth factor; neuroregeneration; neuroprotection; voxel-based morphometry; brain atrophy; cognition; schizophrenia"],["dc.title","Recombinant human erythropoietin delays loss of gray matter in chronic schizophrenia"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]